Hong Kong: Biocytogen Pharma debuts on HKSE

Biotech company, Biocytogen Pharmaceuticals (Beijing), has raised HK$550m (US$70.1m) through an IPO on the main board of the Hong Kong Stock Exchange. A total of 21.76 million shares were offered globally at HK$25.22 per share. Net proceeds will be about HK$471.1m. Shares were trading at HK$25.25 in Hong Kong on September 5. Since its establishment…

You must be a HMI Subscriber to view this content.

Subscribe Now »